{
    "pmcid": "10518403",
    "qa_pairs": {
        "What is a potential concern regarding the therapeutic use of VNARs in humans?": [
            "Immunogenicity due to their non-human origin",
            "Inability to bind to the spike protein",
            "Lack of thermal stability",
            "Inability to be engineered into different formats"
        ],
        "What is one advantage of VNARs that makes them suitable for targeting rapidly mutating viruses like SARS-CoV-2?": [
            "Ability to recognize conserved epitopes",
            "Ability to bind to non-conserved epitopes",
            "Inability to penetrate tissues",
            "Low thermal and chemical stability"
        ],
        "What is the primary target for neutralizing antibodies, including VNARs, in combating SARS-CoV-2?": [
            "The spike protein of SARS-CoV-2",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What unique structural feature allows VNARs to access cryptic epitopes on antigens?": [
            "A long CDR3 loop and absence of a CDR2 loop",
            "A short CDR3 loop and presence of a CDR2 loop",
            "A long CDR2 loop and absence of a CDR3 loop",
            "A short CDR2 loop and presence of a CDR3 loop"
        ],
        "Which technology is preferred for selecting VNARs against SARS-CoV-2?": [
            "Phage display",
            "CRISPR-Cas9",
            "RNA interference",
            "Flow cytometry"
        ]
    }
}